MaxCyte, Inc. (MXCT)
NASDAQ: MXCT · Real-Time Price · USD
3.490
+0.160 (4.80%)
Nov 20, 2024, 4:00 PM EST - Market closed

Company Description

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally.

Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.

The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols.

It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing.

MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

MaxCyte, Inc.
MaxCyte logo
Country United States
Founded 1999
IPO Date Jul 30, 2021
Industry Medical Devices
Sector Healthcare
Employees 143
CEO Maher Masoud

Contact Details

Address:
9713 Key West Avenue, Suite 400
Rockville, Maryland 20850
United States
Phone 301 944 1700
Website maxcyte.com

Stock Details

Ticker Symbol MXCT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $13.00
CIK Code 0001287098
CUSIP Number 57777K106
ISIN Number US57777K1060
Employer ID 52-2210438
SIC Code 8731

Key Executives

Name Position
Maher Masoud President, Chief Executive Officer and Executive Director
Douglas Arthur Doerfler Founder
Douglas J. Swirsky CFA, CPA Chief Financial Officer
Jay Gelfman Senior Vice President of Operations
Ronald Evan Holtz CPA, Ph.D. Executive Vice President of Administration
David Sandoval Senior Vice President, General Counsel and Corporate Secretary
Thomas Michael Ross Executive Vice President of Global Sales
Jack Horgan Vice President of Corporate Development
Jill Mayer Senior Vice President of Human Resources
Dr. J. Stark Thompson Ph.D. Consultant

Latest SEC Filings

Date Type Title
Nov 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 6, 2024 10-Q Quarterly Report
Nov 6, 2024 8-K Current Report
Oct 31, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 21, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 15, 2024 8-K Current Report
Sep 26, 2024 144 Filing
Sep 3, 2024 144 Filing
Aug 6, 2024 10-Q Quarterly Report